ORR-话题@MedSci - 梅斯（MedSci）

#ORR#

59篇内容 | 2091人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1590714, encodeId=fba51590e1471, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=NEJM丨肺癌，KRAS新药adagrasib再显锋芒，ORR高达42.9%, objectType=article, longId=735026, objectId=d8ade35026be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8ade35026be, replyNumber=0, likeNumber=68, createdTime=2022-08-08, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8ade35026be, moduleTitle=NEJM丨肺癌，KRAS新药adagrasib再显锋芒，ORR高达42.9%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d8ade35026be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590713, encodeId=d5d01590e135e, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=ASCO 2022 | 新辅助化疗对Borrmann Ⅳ型胃癌疗效有限, objectType=article, longId=728530, objectId=7500e285305a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7500e285305a, replyNumber=0, likeNumber=97, createdTime=2022-06-04, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7500e285305a, moduleTitle=ASCO 2022 | 新辅助化疗对Borrmann Ⅳ型胃癌疗效有限, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7500e285305a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590712, encodeId=b4e61590e12cb, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR, objectType=article, longId=726862, objectId=923fe2686288, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=923fe2686288, replyNumber=0, likeNumber=110, createdTime=2022-05-16, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=923fe2686288, moduleTitle=通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=923fe2686288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590711, encodeId=94e51590e11e9, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！, objectType=article, longId=724037, objectId=8223e24037e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8223e24037e2, replyNumber=0, likeNumber=95, createdTime=2022-04-13, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8223e24037e2, moduleTitle=2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8223e24037e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590710, encodeId=64241590e10e6, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR, objectType=article, longId=292663, objectId=79a729266362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79a729266362, replyNumber=0, likeNumber=79, createdTime=2021-12-25, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79a729266362, moduleTitle=Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=79a729266362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590709, encodeId=ed6b1590e0929, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=JCO丨肺癌20ins突变，Amivantamab后线治疗ORR高达40%, objectType=article, longId=292282, objectId=e27c2922825e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e27c2922825e, replyNumber=0, likeNumber=99, createdTime=2021-12-22, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e27c2922825e, moduleTitle=JCO丨肺癌20ins突变，Amivantamab后线治疗ORR高达40%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e27c2922825e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590708, encodeId=74711590e08a1, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=新一代ADC类药物ARX788对HER2阳性乳腺癌ORR达74%, objectType=article, longId=215485, objectId=ed4b21548574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed4b21548574, replyNumber=0, likeNumber=70, createdTime=2021-08-11, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed4b21548574, moduleTitle=新一代ADC类药物ARX788对HER2阳性乳腺癌ORR达74%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ed4b21548574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590707, encodeId=2e321590e07b7, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR, objectType=article, longId=207913, objectId=49ca20e9132b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49ca20e9132b, replyNumber=0, likeNumber=74, createdTime=2021-03-07, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49ca20e9132b, moduleTitle=BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=49ca20e9132b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590706, encodeId=ee421590e06ca, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, objectType=article, longId=207818, objectId=f15320e81875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15320e81875, replyNumber=0, likeNumber=67, createdTime=2021-03-04, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15320e81875, moduleTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f15320e81875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590705, encodeId=33f51590e055d, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％, objectType=article, longId=206737, objectId=4e1b206e376a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1b206e376a, replyNumber=0, likeNumber=96, createdTime=2021-02-05, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1b206e376a, moduleTitle=JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4e1b206e376a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590704, encodeId=6cb31590e0403, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％, objectType=article, longId=206520, objectId=2862206520fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2862206520fd, replyNumber=0, likeNumber=72, createdTime=2021-02-02, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2862206520fd, moduleTitle=Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2862206520fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590703, encodeId=ba5c1590e03db, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌, objectType=article, longId=206244, objectId=febb2062446f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=febb2062446f, replyNumber=0, likeNumber=70, createdTime=2021-01-27, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=febb2062446f, moduleTitle=PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=febb2062446f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590702, encodeId=91de1590e027a, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=傻傻分不清 || ORR、DCR、PFS、OS，评价肿瘤结局的客观指标是什么？, objectType=article, longId=206064, objectId=3a042060646e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a042060646e, replyNumber=0, likeNumber=118, createdTime=2021-01-24, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a042060646e, moduleTitle=傻傻分不清 || ORR、DCR、PFS、OS，评价肿瘤结局的客观指标是什么？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3a042060646e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590701, encodeId=9dec1590e012f, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, objectType=article, longId=193181, objectId=fa86193181f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa86193181f6, replyNumber=0, likeNumber=98, createdTime=2020-05-01, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa86193181f6, moduleTitle=AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fa86193181f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590700, encodeId=53881590e0023, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=AACR 2020：伯瑞替尼治疗MET异常NSCLC，ORR达30.5%, objectType=article, longId=193168, objectId=64ac1931686b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64ac1931686b, replyNumber=0, likeNumber=72, createdTime=2020-05-01, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64ac1931686b, moduleTitle=AACR 2020：伯瑞替尼治疗MET异常NSCLC，ORR达30.5%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=64ac1931686b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590699, encodeId=bb7a159069907, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%, objectType=article, longId=192587, objectId=6b7419258e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b7419258e79, replyNumber=0, likeNumber=66, createdTime=2020-04-22, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b7419258e79, moduleTitle=JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6b7419258e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590698, encodeId=0b2c15906985d, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=NSCLC一线治疗：LAG-3抗体显著增强Keytruda的疗效，ORR达到47%！, objectType=article, longId=188600, objectId=906b18860063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=906b18860063, replyNumber=0, likeNumber=76, createdTime=2020-02-24, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=906b18860063, moduleTitle=NSCLC一线治疗：LAG-3抗体显著增强Keytruda的疗效，ORR达到47%！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=906b18860063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590697, encodeId=408f159069e62, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=具备更好的靶选择性，ORR超过88%！复发难治慢性淋巴细胞白血病/小细胞淋巴瘤带来治疗新选择, objectType=article, longId=184372, objectId=a2ac1843e2f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2ac1843e2f7, replyNumber=0, likeNumber=67, createdTime=2019-12-08, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2ac1843e2f7, moduleTitle=具备更好的靶选择性，ORR超过88%！复发难治慢性淋巴细胞白血病/小细胞淋巴瘤带来治疗新选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a2ac1843e2f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590696, encodeId=8d7815906969f, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, objectType=article, longId=163455, objectId=500616345538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500616345538, replyNumber=0, likeNumber=58, createdTime=2019-04-04, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500616345538, moduleTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=500616345538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590695, encodeId=8711159069550, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, objectTitle=BioCorRx与IRISYS合作生产用于治疗阿片类药物使用障碍的纳曲酮植入物, objectType=article, longId=161429, objectId=c47316142968, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c47316142968, replyNumber=0, likeNumber=0, createdTime=2019-03-02, rootId=0, userName=psybestwish, userId=8a7b17846501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c47316142968, moduleTitle=BioCorRx与IRISYS合作生产用于治疗阿片类药物使用障碍的纳曲酮植入物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c47316142968)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ORR

2020-05-29

psybestwish (审核中...)

前往app查看评论内容

#ORR#

NEJM丨肺癌，KRAS新药adagrasib再显锋芒，ORR高达42.9%

2022-08-08

psybestwish (审核中...)

前往app查看评论内容

#ORR#

ASCO 2022 | 新辅助化疗对Borrmann Ⅳ型胃癌疗效有限

2022-06-04

psybestwish (审核中...)

前往app查看评论内容

#ORR#

通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR

2022-05-16

psybestwish (审核中...)

前往app查看评论内容

#ORR#

2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！

2022-04-13

psybestwish (审核中...)

前往app查看评论内容

#ORR#

Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR

2021-12-25

psybestwish (审核中...)

前往app查看评论内容

#ORR#

JCO丨肺癌20ins突变，Amivantamab后线治疗ORR高达40%

2021-12-22

psybestwish (审核中...)

前往app查看评论内容

#ORR#

新一代ADC类药物ARX788对HER2阳性乳腺癌ORR达74%

2021-08-11

psybestwish (审核中...)

前往app查看评论内容

#ORR#

BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR

2021-03-07

psybestwish (审核中...)

前往app查看评论内容

#ORR#

JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%

2021-03-04

psybestwish (审核中...)

前往app查看评论内容

#ORR#

JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％

2021-02-05

psybestwish (审核中...)

前往app查看评论内容

#ORR#

Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％

2021-02-02

psybestwish (审核中...)

前往app查看评论内容

#ORR#

PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌

2021-01-27

psybestwish (审核中...)

前往app查看评论内容

#ORR#

傻傻分不清 || ORR、DCR、PFS、OS，评价肿瘤结局的客观指标是什么？

2021-01-24

psybestwish (审核中...)

前往app查看评论内容

#ORR#

AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%

2020-05-01

psybestwish (审核中...)

前往app查看评论内容

#ORR#

AACR 2020：伯瑞替尼治疗MET异常NSCLC，ORR达30.5%

2020-05-01

psybestwish (审核中...)

前往app查看评论内容

#ORR#

JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%

2020-04-22

psybestwish (审核中...)

前往app查看评论内容

#ORR#

NSCLC一线治疗：LAG-3抗体显著增强Keytruda的疗效，ORR达到47%！

2020-02-24

psybestwish (审核中...)

前往app查看评论内容

#ORR#

具备更好的靶选择性，ORR超过88%！复发难治慢性淋巴细胞白血病/小细胞淋巴瘤带来治疗新选择

2019-12-08

psybestwish (审核中...)

前往app查看评论内容

#ORR#

AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％

2019-04-04

psybestwish (审核中...)

前往app查看评论内容

#ORR#

BioCorRx与IRISYS合作生产用于治疗阿片类药物使用障碍的纳曲酮植入物

2019-03-02

科室
- - 订阅+
  - 更多科室
工具
服务